<DOC>
	<DOCNO>NCT00196378</DOCNO>
	<brief_summary>This two-arm , randomize , double-blind , parallel-group , placebo-controlled study evaluate efficacy Enjuvia 0.3 mg tablet treatment moderate severe symptom vulvovaginal atrophy postmenopausal woman without hysterectomy and/or oophorectomy .</brief_summary>
	<brief_title>A Clinical Trial Evaluate Safety Efficacy Enjuvia 0.3 mg Treatment Vulvovaginal Atrophy</brief_title>
	<detailed_description>The study include screen period 4 week 12-week treatment period . The overall study duration participant approximately 16 week . Study participant undergo physical gynecological exam , blood test clinical laboratory assessment . All patient uterus undergo transvaginal ultrasound .</detailed_description>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Estrogens , Conjugated ( USP )</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Estrogens , conjugate synthetic B</mesh_term>
	<mesh_term>Estrogens , conjugate synthetic A</mesh_term>
	<criteria>Naturally surgically postmenopausal Moderate severe symptom vaginal atrophy ( ie , dryness , itching , pain , uncomfortable intercourse ) Known sensitivity contraindication estrogens progestins History current diagnosis endometrial hyperplasia Recent history vaginal bleed unknown cause Recent history diagnosis endometriosis Any contraindication estrogen therapy</criteria>
	<gender>Female</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>vaginal atrophy</keyword>
	<keyword>vaginal dryness</keyword>
	<keyword>vaginal itching</keyword>
	<keyword>vaginal pain</keyword>
	<keyword>dyspareunia</keyword>
</DOC>